Beyond the Guidelines: Optimizing the Management of SSc-ILD

 

 

PROGRAM OVERVIEW

Interstitial lung disease (ILD) is associated with early mortality and is the most frequent cause of death among individuals with systemic sclerosis (SSc). Over the past several years, there has been a dramatic increase in awareness of the risk for SSc-ILD, and the need for early diagnosis and treatment to improve health outcomes. Nevertheless, accomplishment of this goal remains difficult for several reasons, including the significant challenge associated with accurately identifying patients at risk for rapidly progressive disease.

FACULTY

Kristin Highland, MD
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, Ohio

 

Steven D. Nathan, MD
Medical Director, Lung Transplant Program
Director, Advanced Lung Disease Program
Co-director, Inova Pulmonary Hypertension Program
Inova Fairfax Hospital
Fairfax, Virginia

 

Release date: June 25, 2020
Expiration date: June 25, 2021
Estimated time to complete activity: 0.75 hour

 

TARGET AUDIENCE

This educational initiative has been designed for pulmonologists, rheumatologists, and internal medicine physicians involved in the care of patients with SSc-ILD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Implement best practice recommendations for ILD screening and assessment of risk for progressive ILD in patients with SSc
  • Outline a tailored approach to SSc-ILD treatment that is consistent with current clinical trial evidence of new regimens
  • Utilize communication strategies that facilitate accurate symptom reporting, improve disease understanding, and promote treatment adherence among patients with SSc-ILD
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 25, 2020 and June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Kristin Highland, MD
Consulting Fees: Actelion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., United Therapeutics
Speakers’ Bureaus: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Gilead Sciences, United Therapeutics
Contracted Research: Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Eiger Pharmaceuticals, Genentech, Gossamer Bio, Reata Pharmaceuticals, United Therapeutics

Steven D. Nathan, MD
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc., Galapagos, Roche-Genentech
Speakers’ Bureaus: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

 

Continue to Pretest